Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Update on the treatment of patients with non-genotype 1 hepatitis C virus infection.

Mangia A, Mottola L, Piazzolla V.

Clin Infect Dis. 2013 May;56(9):1294-300. doi: 10.1093/cid/cis1195. Epub 2012 Dec 27. Review.

PMID:
23271787
2.

An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin.

Kondo C, Atsukawa M, Tsubota A, Itokawa N, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Narahara Y, Nakatsuka K, Kanazawa H, Sakamoto C.

J Viral Hepat. 2012 Sep;19(9):615-22. doi: 10.1111/j.1365-2893.2011.01584.x. Epub 2012 Feb 9.

PMID:
22863265
3.

Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin.

Liu CH, Liang CC, Liu CJ, Tseng TC, Lin CL, Yang SS, Su TH, Lin JW, Chen JH, Chen PJ, Chen DS, Kao JH.

Antivir Ther. 2012;17(6):1059-67. doi: 10.3851/IMP2322. Epub 2012 Aug 17.

PMID:
22898703
4.

Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: a multicenter study.

Toyoda H, Kumada T, Shimada N, Takaguchi K, Ide T, Sata M, Ginba H, Matsuyama K, Izumi N.

J Med Virol. 2013 Jan;85(1):65-70. doi: 10.1002/jmv.23428.

PMID:
23154876
5.

Predictive value of early viral dynamics during peginterferon and ribavirin combination therapy based on genetic polymorphisms near the IL28B gene in patients infected with HCV genotype 1b.

Toyoda H, Kumada T, Tada T, Hayashi K, Honda T, Katano Y, Goto H, Kawaguchi T, Murakami Y, Matsuda F.

J Med Virol. 2012 Jan;84(1):61-70. doi: 10.1002/jmv.22272.

PMID:
22095536
6.

Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy.

Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2012 Oct;84(10):1593-9. doi: 10.1002/jmv.23368.

PMID:
22930507
7.

A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.

Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA.

Clin Gastroenterol Hepatol. 2011 Jun;9(6):509-516.e1. doi: 10.1016/j.cgh.2011.03.004. Epub 2011 Mar 11.

PMID:
21397729
8.

Individualisation of antiviral therapy for chronic hepatitis C.

Teoh NC, Farrell GC, Chan HL.

J Gastroenterol Hepatol. 2010 Jul;25(7):1206-16. doi: 10.1111/j.1440-1746.2010.06392.x. Review.

PMID:
20594246
9.

Treatment of chronic hepatitis C in Asia: when East meets West.

Yu ML, Chuang WL.

J Gastroenterol Hepatol. 2009 Mar;24(3):336-45. doi: 10.1111/j.1440-1746.2009.05789.x. Review.

PMID:
19335784
10.

Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.

Yu ML, Chuang WL, Dai CY, Lee LP, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Tsai SL, Kuo HT.

Transl Res. 2006 Sep;148(3):120-7.

PMID:
16938649
11.

Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4.

Rivero-Juárez A, Camacho Espejo A, Perez-Camacho I, Neukam K, Caruz A, Mira JA, Mesa P, García-Lázaro M, Torre-Cisneros J, Pineda JA, Rivero A.

J Antimicrob Chemother. 2012 Jan;67(1):202-5. doi: 10.1093/jac/dkr439. Epub 2011 Oct 11.

PMID:
21990051
12.

Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: a meta-analysis.

Cammà C, Cabibbo G, Bronte F, Enea M, Licata A, Attanasio M, Andriulli A, Craxì A.

J Hepatol. 2009 Oct;51(4):675-81. doi: 10.1016/j.jhep.2009.06.018. Epub 2009 Jul 15.

PMID:
19665247
13.

Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin.

Huang CF, Huang JF, Yang JF, Hsieh MY, Lin ZY, Chen SC, Wang LY, Juo SH, Chen KC, Chuang WL, Kuo HT, Dai CY, Yu ML.

J Hepatol. 2012 Jan;56(1):34-40. doi: 10.1016/j.jhep.2011.03.029. Epub 2011 May 19. Erratum in: J Hepatol. 2012 May;56(5):1218.

PMID:
21703176
14.

Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment.

Neukam K, Mira JA, Gilabert I, Claro E, Vázquez MJ, Cifuentes C, García-Rey S, Merchante N, Almeida C, Macías J, Pineda JA.

Eur J Clin Microbiol Infect Dis. 2012 Jun;31(6):1225-32. doi: 10.1007/s10096-011-1433-5. Epub 2011 Oct 6.

PMID:
21971821
15.

[THE USE OF COMBINATION ANTIVIRAL THERAPY IN LIVER CIRRHOSIS HCV ETIOLOGY].

Varlamov V I, Ivanova AL, Tarasova LV.

Eksp Klin Gastroenterol. 2015;(11):92-4. Russian.

PMID:
27214995
16.

[Therapeutic behaviour for a HCV+ patient].

Buffet C.

Presse Med. 2004 Apr 10;33(7):497-8. French. No abstract available.

PMID:
15105775
17.

You're not the one: treating subjects co-infected with hepatitis C genotypes 2 and 3 and human immunodeficiency virus.

Pearlman BL, Lim TH.

Dig Dis Sci. 2014 Aug;59(8):1681-3. doi: 10.1007/s10620-014-3270-8. Epub 2014 Jul 8. No abstract available.

PMID:
25002310
18.

[Evaluation of tolerance and efficacy of the treatment of chronic viral hepatitis C in homozygous sickle cell patients].

El Agheb MO, Grange JD.

Pan Afr Med J. 2015 Feb 4;20:99. doi: 10.11604/pamj.2015.20.99.6003. eCollection 2015. French. No abstract available.

19.

Commentary on: The optimal Dose of Ribavirin for Chronic Hepatitis C: From Literature Evidence to Clinical Practice.

El-Shabrawi M, Isa M.

Hepat Mon. 2013 Feb 28;13(2):e7867. doi: 10.5812/hepatmon.7867. Print 2013 Feb. No abstract available.

20.

Clinical Characteristics and Patterns of Care Among Patients With Genotype 1 (G1) Hepatitis C Virus In Europe (Eu).

Narayanan S, Wilson A, Katz J, Fernando S.

Value Health. 2015 Nov;18(7):A631-2. doi: 10.1016/j.jval.2015.09.2234. Epub 2015 Oct 20. No abstract available.

Supplemental Content

Support Center